SCHAUMBURG, Ill., April 20, 2011 /PRNewswire/ -- Sagent Pharmaceuticals (Nasdaq: SGNT) announced the upsizing and pricing of its initial public offering.

SCHAUMBURG, Ill., April 6, 2011 /PRNewswire/ -- Sagent Pharmaceuticals (the "Company"), announced that it has commenced an initial public offering of 5,000,000 shares of common stock. The estimated range for the initial public offering price is $14.00 to $16.00 per share.

SCHAUMBURG, Ill., April 8 /PRNewswire/ -- Sagent Pharmaceuticals, a privately held specialty pharmaceutical company, announced today that it has raised $40 million through two tranches of a strategic Series B financing.

Sagent Pharmaceuticals, a privately-held specialty pharmaceutical company, and Itochu Chemical Frontier, a privately-held company in the field of pharmaceutical and organic and fine chemicals based in Japan, have signed a development and supply collaboration agreement.

Spectrum Pharmaceuticals has sold its abbreviated new drug applications for its injectable generic drugs, ondansetron, carboplatin, fludarabine, and mitoxantrone, to Sagent Pharmaceuticals.